Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Operating Leases (2019 - 2025)

Vistagen Therapeutics' Operating Leases history spans 6 years, with the latest figure at $431000.0 for Q4 2025.

  • For Q4 2025, Operating Leases fell 61.17% year-over-year to $431000.0; the TTM value through Dec 2025 reached $431000.0, down 61.17%, while the annual FY2025 figure was $948000.0, 39.62% down from the prior year.
  • Operating Leases for Q4 2025 was $431000.0 at Vistagen Therapeutics, down from $610000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $3.4 million in Q1 2021 and bottomed at $431000.0 in Q4 2025.
  • The 4-year median for Operating Leases is $1.5 million (2024), against an average of $1.7 million.
  • The largest annual shift saw Operating Leases fell 11.32% in 2021 before it tumbled 61.17% in 2025.
  • A 4-year view of Operating Leases shows it stood at $2.7 million in 2021, then tumbled by 36.95% to $1.7 million in 2023, then crashed by 35.21% to $1.1 million in 2024, then crashed by 61.17% to $431000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Operating Leases are $431000.0 (Q4 2025), $610000.0 (Q3 2025), and $783000.0 (Q2 2025).